# Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine

> **NCT06181292** · PHASE2,PHASE3 · COMPLETED · sponsor: **Hipra Scientific, S.L.U** · enrollment: 913 (actual)

## Conditions studied

- SARS-CoV2 Infection

## Interventions

- **BIOLOGICAL:** PHH-1V81
- **BIOLOGICAL:** Comirnaty Omicron XBB1.5

## Key facts

- **NCT ID:** NCT06181292
- **Lead sponsor:** Hipra Scientific, S.L.U
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-15
- **Primary completion:** 2024-06-17
- **Final completion:** 2024-06-17
- **Target enrollment:** 913 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06181292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06181292, "Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06181292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*